State of Emerging Therapeutic Company Investment, Deal-making, and Pipeline

8:00 AM - 9:00 AM (PDT), Tuesday, June 9, 2020
Search General Info
Search Education
Search Partnering Companies
David Thomas, BIO’s Vice President of Industry Analysis, will provide an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the rapidly changing COVID-19 R&D pipeline. The BIO Industry Analysis team has published the COVID Pipeline Tracker at bio.org/covidpipelinetracker, and will soon publish annual investment and deal data at bio.org/iareports. Data for the following areas will be presented: licensing, M&A, venture capital, IPOs, follow-on public offerings, and a new Digital Health deal breakdown of Clarivate data.

Please note this session was pre-recorded but make sure to engage in the live Q & A chat.
BIO’s President & CEO, Dr. Michelle McMurry-Heath will hold a moment of silence for George Floyd during the plenary session at 11:00 am PDT.
Speaker
photo
Vice President, Industry Research
Biotechnology Innovation Organization